ArticleCancer biology & therapy2014

Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.

Yan Zang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.